

Part VI: Summary of the risk management plan

Summary of risk management plan for Allopurinol “Medical Valley” (allopurinol)

This is a summary of the risk management plan (RMP) for Allopurinol “Medical Valley”. The RMP details important risks of Allopurinol “Medical Valley” and how more information will be obtained about Allopurinol “Medical Valley”’s risks and uncertainties (missing information).

Allopurinol “Medical Valley”’s summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Allopurinol “Medical Valley” should be used.

Important new concerns or changes to the current ones will be included in updates of Allopurinol “Medical Valley”’s RMP.

I. The medicine and what it is used for

Allopurinol “Medical Valley” is authorised for:

- reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy).
- the management of 2, 8-dihydroxyadenine (2, 8-DHA) renal stones related to deficient activity of adenine phosphoribosyltransferase.
- the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.

Children and adolescents:

- Secondary hyperuricaemia of differing origin
- Uric acid nephropathy during treatment of leukaemia
- Hereditary enzyme deficiency disorders, Lesch-Nyhan syndrome (partial or total hypoxanthin-guanin phosphoribosyl transferase deficiency) and adenine phosphoribosyl transferase deficiency.

See SmPC for the full indication.

It contains allopurinol as the active substance, and it is given by the oral route.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Allopurinol “Medical Valley”, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of Allopurinol "Medical Valley" is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Allopurinol "Medical Valley" are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Allopurinol "Medical Valley". Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

List of important risks and missing information	
Important identified risks	Hypersensitivity reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis
Important potential risks	None
Missing information	Use in pregnant women

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Allopurinol "Medical Valley".

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Allopurinol "Medical Valley".